(Sharecast News) - Medical diagnostics company Omega revealed on Thursday that its CE-Marked Mologic ELISA antibody test had been approved for Covid-19 testing in India.
Omega said the Central Drugs Standard Control Organization, part of India's Ministry of Health and Family Welfare, had published a list of kits approved for testing of Covid-19 on Wednesday, which included Omega's ELISA antibody test.
The AIM-listed group said approval for sale remained conditional on the submission of supporting technical data, of which the company said it was "confident" it would be successful, granting the firm the ability to sell its antibody test directly into the "potentially significant target market".
While Omega said "the quantum of future sales" was unknown at present, it highlighted that India was "clearly a significant addressable market".
Chief executive Colin King said: "We have an established direct sales team and we believe a reliable and high-performance antibody test will be very attractive to our laboratory customers.
"Clearly this is an important market for us to target and I look forward to updating shareholders on our commercial traction."
As of 0925 BST, Omega shares were up 0.74% at 41p.
7 Sep 2020 14:50
IN BRIEF: Omega Diagnostics Completes AbC-19 Self-Test Usability Study
IN BRIEF: Omega Diagnostics Completes AbC-19 Self-Test Usability Study
Read more